Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schulz, E; Aplan, PD; Freeman, SD; Pavletic, SZ.
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
Blood Adv. 2023; 7(16):4381-4394
Doi: 10.1182/bloodadvances.2023010098
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Schulz Eduard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Approximately 90% of patients with myelodysplastic syndromes (MDSs) have somatic mutations that are known or suspected to be oncogenic in the malignant cells. The genetic risk stratification of MDSs has evolved substantially with the introduction of the clinical molecular international prognostic scoring system, which establishes next-generation sequencing at diagnosis as a standard of care. Furthermore, the International Consensus Classification of myeloid neoplasms and acute leukemias has refined the MDS diagnostic criteria with the introduction of a new MDS/acute myeloid leukemia category. Monitoring measurable residual disease (MRD) has historically been used to define remission status, improve relapse prediction, and determine the efficacy of antileukemic drugs in patients with acute and chronic leukemias. However, in contrast to leukemias, assessment of MRD, including tracking of patient-specific mutations, has not yet been formally defined as a biomarker for MDS. This article summarizes current evidence and challenges and provides a conceptual framework for incorporating MRD into the treatment of MDS and future clinical trials.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Concept Formation - administration & dosage
- Mutation - administration & dosage
- Myelodysplastic Syndromes - diagnosis, therapy, genetics
- Risk Factors - administration & dosage
- Leukemia, Myeloid, Acute - genetics
- Neoplasm, Residual - diagnosis